Navigation Links
Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Date:9/20/2012

MONTREAL, Sept. 20, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) (the "Company") announced today that VPI Escrow Corp., a newly formed wholly owned Delaware subsidiary of Valeant Pharmaceuticals International ("Valeant"), a wholly owned indirect subsidiary of the Company, has priced its previously announced offering of $1,750 million aggregate principal amount of 6.375% senior unsecured notes due 2020 (the "Notes"). The offering is expected to close on or about October 4, 2012. The net proceeds of the offering are expected to be used to fund (i) the transactions contemplated by the previously announced Agreement and Plan of Merger ("Merger Agreement") with Medicis Pharmaceutical Corporation ("Medicis") whereby Medicis will continue as a wholly owned subsidiary of Valeant, (ii) Medicis's obligation to pay the conversion consideration with respect to, or repurchase, its outstanding notes, and (iii) transaction expenses in connection with the Merger Agreement.

Additionally, the Company also announced that Valeant has priced its previously announced offering of $500 million aggregate principal amount of 6.375% senior unsecured notes due 2020 (the "Concurrent Notes"). The offering is expected to close on or about October 4, 2012. Valeant intends to use the net proceeds of the offering for general corporate purposes, including potential acquisitions.

The Notes and the Concurrent Notes will be guaranteed by the Company and each of the Company's subsidiaries (other than Valeant) that is a guarantor of the Company and Valeant's senior secured credit facilities.

Neither the Notes nor the Concurrent Notes will be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes and the Concurrent Notes will be offered in the United States only to qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. Neither the Notes nor the Concurrent Notes have been nor will be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.

Caution Regarding Forward-Looking Information and "Safe Harbor" Statement
This press release may contain forward-looking statements, including, but not limited to, the expected closing of the offerings, the expected use of proceeds from the offerings and the guarantees that will be provided in relation to the Notes and the Concurrent Notes. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and risks and uncertainties relating to the proposed merger, as detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
2. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
3. Valeant Pharmaceuticals To Syndicate Incremental Loans
4. Valeant Pharmaceuticals Announces Management Change
5. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
6. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
7. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
8. Valeant Pharmaceuticals To Host Investor Day
9. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
10. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
11. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... 2016 194 Mitgliedsstaaten ... Eliminierung von viraler Hepatitis    Am ... eingegangen, virale Hepatitis bis 2030 zu eliminieren. ... Assembly haben sich die Staaten einstimmig dafür entschieden, ... Viral Hepatitis Strategy) zu verabschieden, was das bisher ...
(Date:5/30/2016)... , May 30, 2016 ... "Healthcare Analytical Testing Services Market by Type (Stability, ... Services), by End User (Pharmaceutical Companies, Medical Device ... MarketsandMarkets, The market witnessed healthy growth during the ... a CAGR of 11.3% between 2016 and 2021 ...
(Date:5/30/2016)... , May 30, 2016 ... 2016" market research report with comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... 31, 2016 , ... Spartan Bioscience today introduced the Spartan ... convenience. , The Cube is exceptionally small—it takes up the space of a ... into any space, whether in a hospital, doctor’s office, or pharmacy. , The ...
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, ... know – London is home to Ontario’s leading day spa and one of Canada’s ... Tamba began with a unique concept to combine spa services with hair and ...
(Date:5/31/2016)... ... ... In his latest video, renowned AstroNumerologist Jesse Kalsi reveals ... candidate Donald Trump as an example, Kalsi describes the way AstroNumerology conveys the ... numbers up,” says Kalsi. “It is about looking at each individual number, since ...
(Date:5/31/2016)... ... 31, 2016 , ... Interest is on the rise for using the CRISPR-Cas9 ... tool for RNAi hit validation. A key reason may be that high-throughput synthesis—combined with ... CRISPR RNA (crRNA) collections in arrayed formats. , Arrayed crRNA screens ...
(Date:5/31/2016)... ... , ... In a recent interview on The Greenburgh Report radio show hosted ... WVOX (1460 AM), leading medical insurance advocate Adria Goldman Gross discussed several eye-opening ... maelstrom.” , During the interview with Mr. Feiner that aired on May 7, ...
Breaking Medicine News(10 mins):